{"id":739817,"date":"2023-03-14T08:15:39","date_gmt":"2023-03-14T12:15:39","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/proteovant-therapeutics-to-present-preclinical-data-from-estrogen-receptor-and-ikzf2-protein-degrader-programs\/"},"modified":"2023-03-14T08:15:39","modified_gmt":"2023-03-14T12:15:39","slug":"proteovant-therapeutics-to-present-preclinical-data-from-estrogen-receptor-and-ikzf2-protein-degrader-programs","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/proteovant-therapeutics-to-present-preclinical-data-from-estrogen-receptor-and-ikzf2-protein-degrader-programs\/","title":{"rendered":"Proteovant Therapeutics to Present Preclinical Data from Estrogen Receptor and IKZF2 Protein Degrader Programs"},"content":{"rendered":"

\nPVTX-321 and PVTX-405 Achieve Development Candidate Nomination
\n<\/h2>\n
\n

NEW YORK, March 14, 2023 (GLOBE NEWSWIRE) — Proteovant Therapeutics<\/a>,\u00a0a\u00a0Roivant Sciences (Nasdaq: ROIV) company leveraging the process of protein degradation to discover and develop transformative medicines for the treatment of patients with life-altering diseases, today announced it will present data on PVTX-321, an estrogen receptor degrader, at the Protein Degradation & Targeting Undruggables Congress USA, March 15-16 in Boston and on PVTX-405, an IKZF2 molecular glue, at the Targeted Protein Degradation Europe Conference, March 28-30 in London.<\/p>\n

Targeted protein degradation harnesses the body\u2019s natural protein disposal system and offers the potential to develop new medicines targeting historically difficult-to-drug proteins that play an important role in causing serious diseases. Proteovant Therapeutics is discovering and developing best-in-class and first-in-class degraders that can engage previously undruggable targets.<\/p>\n

\u201cWe are advancing a robust pipeline of heterobifunctional degraders and molecular glues that span a range of novel molecular targets, which are implicated in disorders where new medicines are needed,\u201d said Drew Fromkin, CEO, Proteovant Therapeutics. \u201cPVTX-321, our degrader targeting the estrogen receptor, is highly potent and demonstrates impressive, dose dependent tumor growth inhibition and shrinkage in preclinical models. In addition, PVTX-405 has best-in-class potential with robust IKZF2 degradation in vivo. We are enthusiastic about the progress being made across our degrader pipeline and molecular glue platform initiatives.\u201d<\/p>\n

\n Presentation at <\/strong>
\n
\n Protein Degradation & Targeting Undruggables Congress USA<\/strong>
\n <\/a>\n <\/p>\n